Vegf, vegf-B, vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa

André, Thierry; Kotelevets, Larissa; Coudray, Anne Marie; Weber, Laurence; Prévôt, Sophie; Parc, R; Gespach, Christian; Chastre, Eric

doi:10.1002/(sici)1097-0215(20000415)86:2<174::aid-ijc5>3.3.co;2-5

Cited by 31 publications

(42 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…41 Many articles have described that tumor cells mainly express VEGF 121 and VEGF 165 isoforms. 36,42 Our results support these previous reports. High expression of VEGF 165 mRNA was shown in Figure 1b and only VEGF 165 protein of 40-kDa was detected in the CM of OUMS-27 cells (Fig.…”

Section: Discussionsupporting

confidence: 92%

“…The VEGF 145 isoform was detected by RT-PCR (failed to be detected by Northern blot analysis) in endometrial adenocarcinoma cells stimulated with insulin-like growth factor-1. 44 Although previous studies 36,42 could not detect VEGF 145 except in female inherent tissue, we obtained the first finding that the VEGF 145 isoform is also exhibited in a male chondrosarcoma. VEGF 145 has been reported as a specific protein that binds to ECM produced in corneal endothelial cells by a different mechanism.…”

Section: Discussionmentioning

confidence: 51%

See 1 more Smart Citation

Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth

Furumatsu

Nishida

Kawai

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 51%

Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth

Furumatsu

Nishida

Kawai

et al. 2001

Intl Journal of Cancer

View full text Add to dashboard Cite

“…The mRNA findings of the study were confirmed by immunohistochemistry, which showed no correlation between positive staining for VEGF-A, VEGF-C or VEGF-D and lymphatic spread (George et al, 2001). Further analyses of VEGF family mRNA levels in the adenoma -carcinoma sequence showed that of VEGF-A, VEGF-B and VEGF-C, only VEGF-A mRNA levels were consistently raised in invasive malignancy and this became apparent early on in disease progression, as levels were elevated to a similar extent in tumours with and without lymph node metastases or distant spread (Andre et al, 2000).…”

Section: Colorectal Cancermentioning

confidence: 99%

Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy

Duff

Jeziorska

et al. 2003

Br J Cancer

View full text Add to dashboard Cite

“…Tumor-related neovascularization plays a critical role in colorectal cancer progression, and this has been well documented (11,12). Several studies have shown that VEGF expression is increased in the progression from nonmalignant to malignant colon tumors (13 -15).…”

Section: Introductionmentioning

confidence: 99%

Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases

Troiani

Lockerbie

Morrow

et al. 2006

Molecular Cancer Therapeutics

View full text Add to dashboard Cite

To date, clinical studies combining the new generation of targeted therapies and chemotherapy have had mixed results. Preclinical studies can be used to identify potential antagonism/synergy between certain agents, with the potential to predict the most efficacious combinations for further investigation in the clinical setting. In this study, we investigated the sequence-dependent interactions of ZD6474 with oxaliplatin in two human colon cell lines in vitro. We evaluated the in vitro antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor (VEGFR), epidermal growth factor receptor (EGFR) and RET tyrosine kinase activity, and oxaliplatin using three combination schedules: ZD6474 before oxaliplatin, oxaliplatin before ZD6474, and concurrent exposure. Cell proliferation studies showed that treatment with oxaliplatin followed by ZD6474 was highly synergistic, whereas the reverse sequence was clearly antagonistic as was concurrent exposure. Oxaliplatin induced a G 2 -M arrest, which was antagonized if the cells were previously or concurrently treated with ZD6474. ZD6474 enhanced oxaliplatin-induced apoptosis but only when added after oxaliplatin. The sequence-dependent antitumor effects appeared, in part, to be based on modulation of compensatory prosurvival pathways. Thus, expression of total and active phosphorylated EGFR, as well as AKT and extracellular signal-regulated kinase, was markedly increased by oxaliplatin. This increase was blocked by subsequent treatment with ZD6474. Furthermore, the synergistic sequence resulted in reduced expression of insulin-like growth factor-I receptor and a marked reduction in secretion of vascular endothelial growth factor protein. ZD6474 in combination with oxaliplatin has synergistic antiproliferative properties in human colorectal cancer cell lines in vitro when oxaliplatin is administered before ZD6474.

show abstract

Vegf, vegf-B, vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa

Cited by 31 publications

References 14 publications

Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth

Human chondrosarcoma secretes vascular endothelial growth factor to induce tumor angiogenesis and stores basic fibroblast growth factor for regulation of its own growth

Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy

Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases

Contact Info

Product

Resources

About